119 related articles for article (PubMed ID: 26056008)
1. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.
Ahmad S; Johnson GL; Scott JE
Biochem Biophys Res Commun; 2015 Aug; 463(4):888-93. PubMed ID: 26056008
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors.
Ahmad S; Hughes MA; Johnson GL; Scott JE
J Biomol Screen; 2013 Apr; 18(4):388-99. PubMed ID: 23134735
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).
Ahmad S; St Hilaire VR; Dandepally SR; Johnson GL; Williams AL; Scott JE
Biochem Biophys Res Commun; 2018 Jan; 496(1):205-211. PubMed ID: 29309787
[TBL] [Abstract][Full Text] [Related]
4. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I.
Bok S; Shin DY; Yallowitz AR; Eiseman M; Cung M; Xu R; Li N; Sun J; Williams AL; Scott JE; Su B; Shim JH; Greenblatt MB
Nat Commun; 2020 Nov; 11(1):5704. PubMed ID: 33177525
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
[No Abstract] [Full Text] [Related]
8. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
9. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways.
Zhang D; Facchinetti V; Wang X; Huang Q; Qin J; Su B
EMBO J; 2006 Jan; 25(1):97-107. PubMed ID: 16362041
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
11. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
[TBL] [Abstract][Full Text] [Related]
12. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
Kanojia D; Garg M; Martinez J; M T A; Luty SB; Doan NB; Said JW; Forscher C; Tyner JW; Koeffler HP
J Hematol Oncol; 2017 Nov; 10(1):173. PubMed ID: 29132397
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
14. Prevention of calpain-dependent degradation of STK38 by MEKK2-mediated phosphorylation.
Enomoto A; Fukasawa T; Tsumoto H; Karube M; Nakagawa K; Yoshizaki A; Sato S; Miura Y; Miyagawa K
Sci Rep; 2019 Nov; 9(1):16010. PubMed ID: 31690749
[TBL] [Abstract][Full Text] [Related]
15. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig
Yoshida T; Leen Liew E; Ota M; Nakayama H; Yanagihara Y; Nakamura Y; Seriu T; Kamishohara M
Nihon Yakurigaku Zasshi; 2017; 150(1):54-61. PubMed ID: 28690276
[No Abstract] [Full Text] [Related]
17. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts.
Kesavan K; Lobel-Rice K; Sun W; Lapadat R; Webb S; Johnson GL; Garrington TP
J Cell Physiol; 2004 Apr; 199(1):140-8. PubMed ID: 14978743
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C alpha, betaI, and betaII isozymes regulate cytokine production in mast cells through MEKK2/ERK5-dependent and -independent pathways.
Li G; Lucas JJ; Gelfand EW
Cell Immunol; 2005 Nov; 238(1):10-8. PubMed ID: 16430878
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro evaluation of imidazopyridazines as novel inhibitors of the malarial kinase PfPK7.
Bouloc N; Large JM; Smiljanic E; Whalley D; Ansell KH; Edlin CD; Bryans JS
Bioorg Med Chem Lett; 2008 Oct; 18(19):5294-8. PubMed ID: 18774709
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
